Jonathan Samuel Hausmann, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rheumatology | 21 | 2023 | 619 | 3.570 |
Why?
|
| Hereditary Autoinflammatory Diseases | 8 | 2023 | 42 | 2.080 |
Why?
|
| Rheumatic Diseases | 12 | 2023 | 658 | 1.700 |
Why?
|
| Mevalonate Kinase Deficiency | 4 | 2022 | 19 | 1.210 |
Why?
|
| Familial Mediterranean Fever | 4 | 2022 | 66 | 1.100 |
Why?
|
| Stomatitis, Aphthous | 3 | 2023 | 51 | 1.080 |
Why?
|
| Fever | 8 | 2023 | 1607 | 1.080 |
Why?
|
| Lymphadenitis | 3 | 2023 | 99 | 1.040 |
Why?
|
| Pharyngitis | 3 | 2023 | 221 | 0.980 |
Why?
|
| Nasopharyngitis | 1 | 2023 | 10 | 0.860 |
Why?
|
| Thermometers | 1 | 2018 | 42 | 0.630 |
Why?
|
| Body Temperature | 1 | 2018 | 780 | 0.500 |
Why?
|
| Autoimmune Diseases | 2 | 2018 | 2254 | 0.440 |
Why?
|
| Health Communication | 1 | 2017 | 216 | 0.440 |
Why?
|
| Musculoskeletal Diseases | 1 | 2019 | 598 | 0.430 |
Why?
|
| Cryopyrin-Associated Periodic Syndromes | 2 | 2022 | 17 | 0.410 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 4 | 2022 | 299 | 0.400 |
Why?
|
| Information Dissemination | 2 | 2020 | 1142 | 0.400 |
Why?
|
| Pandemics | 8 | 2023 | 8735 | 0.370 |
Why?
|
| Education, Medical, Graduate | 2 | 2019 | 2418 | 0.340 |
Why?
|
| Goals | 1 | 2014 | 717 | 0.320 |
Why?
|
| Antirheumatic Agents | 5 | 2021 | 1383 | 0.300 |
Why?
|
| Arthritis, Rheumatoid | 5 | 2023 | 3788 | 0.280 |
Why?
|
| Physicians | 3 | 2023 | 4591 | 0.250 |
Why?
|
| Healthcare Disparities | 1 | 2021 | 3411 | 0.240 |
Why?
|
| Psoriasis | 2 | 2023 | 925 | 0.230 |
Why?
|
| Macrophage Activation Syndrome | 2 | 2022 | 124 | 0.220 |
Why?
|
| Syndrome | 3 | 2023 | 3271 | 0.220 |
Why?
|
| Cytokines | 1 | 2018 | 7438 | 0.220 |
Why?
|
| Turkey | 2 | 2021 | 256 | 0.210 |
Why?
|
| Biological Products | 3 | 2023 | 948 | 0.210 |
Why?
|
| Arthritis, Psoriatic | 2 | 2023 | 219 | 0.200 |
Why?
|
| Colchicine | 2 | 2022 | 257 | 0.200 |
Why?
|
| Registries | 10 | 2023 | 8351 | 0.200 |
Why?
|
| Child | 15 | 2023 | 80668 | 0.190 |
Why?
|
| Fellowships and Scholarships | 2 | 2022 | 1134 | 0.190 |
Why?
|
| Antibodies, Monoclonal | 1 | 2018 | 9244 | 0.190 |
Why?
|
| Lupus Erythematosus, Systemic | 3 | 2022 | 2160 | 0.180 |
Why?
|
| Inflammation | 2 | 2018 | 10860 | 0.180 |
Why?
|
| Humans | 55 | 2023 | 766766 | 0.170 |
Why?
|
| Borna Disease | 1 | 1999 | 1 | 0.170 |
Why?
|
| Borna disease virus | 1 | 1999 | 2 | 0.170 |
Why?
|
| Immunologic Tests | 1 | 2020 | 101 | 0.170 |
Why?
|
| Myositis | 1 | 2022 | 268 | 0.160 |
Why?
|
| Synovial Fluid | 1 | 2021 | 391 | 0.160 |
Why?
|
| Nucleoproteins | 1 | 1999 | 110 | 0.160 |
Why?
|
| Problem-Based Learning | 1 | 2022 | 360 | 0.160 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 2023 | 543 | 0.160 |
Why?
|
| Eosinophilia | 1 | 2023 | 554 | 0.150 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2022 | 273 | 0.150 |
Why?
|
| Glucocorticoids | 4 | 2023 | 2158 | 0.150 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 3110 | 0.150 |
Why?
|
| Cell Polarity | 1 | 2021 | 637 | 0.150 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 3232 | 0.150 |
Why?
|
| Interleukin-1 | 4 | 2023 | 1251 | 0.150 |
Why?
|
| Exanthema | 1 | 2022 | 502 | 0.140 |
Why?
|
| Antipyretics | 2 | 2017 | 22 | 0.140 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2021 | 1044 | 0.140 |
Why?
|
| Immunomodulation | 1 | 2020 | 548 | 0.130 |
Why?
|
| Abdominal Pain | 1 | 2023 | 1069 | 0.130 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2020 | 668 | 0.130 |
Why?
|
| Diarrhea | 1 | 2023 | 1317 | 0.130 |
Why?
|
| Galactose | 1 | 2017 | 299 | 0.130 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2023 | 1126 | 0.120 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2020 | 621 | 0.120 |
Why?
|
| Privacy | 1 | 2017 | 233 | 0.120 |
Why?
|
| Adolescent | 13 | 2023 | 88904 | 0.120 |
Why?
|
| Osteomyelitis | 1 | 2018 | 408 | 0.110 |
Why?
|
| Severity of Illness Index | 6 | 2022 | 15908 | 0.110 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2020 | 1885 | 0.110 |
Why?
|
| Glycosylation | 1 | 2017 | 1099 | 0.110 |
Why?
|
| Antimalarials | 1 | 2020 | 909 | 0.110 |
Why?
|
| Adult | 19 | 2023 | 223307 | 0.110 |
Why?
|
| Spinal Diseases | 1 | 2018 | 561 | 0.110 |
Why?
|
| T-Lymphocytes | 2 | 2021 | 10264 | 0.100 |
Why?
|
| Lung Diseases | 1 | 2023 | 1941 | 0.100 |
Why?
|
| Patient Care Planning | 1 | 2018 | 904 | 0.100 |
Why?
|
| Male | 26 | 2023 | 364142 | 0.100 |
Why?
|
| Curriculum | 2 | 2022 | 3783 | 0.100 |
Why?
|
| Viral Proteins | 1 | 1999 | 1801 | 0.100 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2020 | 2270 | 0.100 |
Why?
|
| Needs Assessment | 1 | 2018 | 1140 | 0.100 |
Why?
|
| Data Collection | 1 | 2021 | 3321 | 0.090 |
Why?
|
| Receptors, Interleukin-1 | 2 | 2022 | 260 | 0.090 |
Why?
|
| Female | 25 | 2023 | 396520 | 0.090 |
Why?
|
| Young Adult | 6 | 2021 | 59939 | 0.090 |
Why?
|
| Child, Preschool | 6 | 2022 | 42577 | 0.090 |
Why?
|
| Hypercalcemia | 1 | 2013 | 425 | 0.090 |
Why?
|
| Polysaccharides | 1 | 2017 | 1020 | 0.090 |
Why?
|
| Health Services Needs and Demand | 1 | 2018 | 1404 | 0.090 |
Why?
|
| Estrogens | 1 | 2017 | 1528 | 0.090 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2018 | 949 | 0.080 |
Why?
|
| Quality of Life | 5 | 2023 | 13476 | 0.080 |
Why?
|
| Internet | 1 | 2021 | 3113 | 0.080 |
Why?
|
| Infant | 5 | 2021 | 36461 | 0.080 |
Why?
|
| Sports | 1 | 2014 | 701 | 0.080 |
Why?
|
| Sarcoidosis | 1 | 2013 | 535 | 0.070 |
Why?
|
| Middle Aged | 15 | 2022 | 223257 | 0.070 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2021 | 2429 | 0.070 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 2006 | 0.070 |
Why?
|
| Hospitalization | 3 | 2021 | 10823 | 0.070 |
Why?
|
| Prednisone | 2 | 2022 | 1566 | 0.070 |
Why?
|
| Biomedical Research | 1 | 2021 | 3459 | 0.060 |
Why?
|
| Immunoglobulin G | 1 | 2017 | 4559 | 0.060 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 3692 | 0.060 |
Why?
|
| Health Status | 1 | 2017 | 4087 | 0.060 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2013 | 1805 | 0.050 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 3927 | 0.050 |
Why?
|
| Mutation | 3 | 2023 | 30213 | 0.050 |
Why?
|
| Education, Medical | 1 | 2014 | 1744 | 0.050 |
Why?
|
| Software | 1 | 2016 | 4466 | 0.050 |
Why?
|
| Prednisolone | 1 | 2022 | 326 | 0.050 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 11920 | 0.040 |
Why?
|
| Spondylarthropathies | 1 | 2020 | 14 | 0.040 |
Why?
|
| Iodine Radioisotopes | 1 | 2004 | 1030 | 0.040 |
Why?
|
| Interleukin-12 | 1 | 2023 | 581 | 0.040 |
Why?
|
| Primary Health Care | 1 | 2017 | 4735 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 26310 | 0.040 |
Why?
|
| Problem Solving | 1 | 2022 | 442 | 0.040 |
Why?
|
| Vaccination | 2 | 2022 | 3434 | 0.040 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2004 | 1143 | 0.040 |
Why?
|
| H-2 Antigens | 1 | 1999 | 359 | 0.040 |
Why?
|
| Spain | 1 | 2020 | 483 | 0.040 |
Why?
|
| Mice, Inbred CBA | 1 | 1999 | 439 | 0.040 |
Why?
|
| Immunoglobulin E | 1 | 2005 | 1495 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2021 | 9661 | 0.040 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 426 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2021 | 41710 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 12985 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2021 | 4410 | 0.040 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2023 | 975 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2021 | 4652 | 0.030 |
Why?
|
| Fertility Agents, Female | 1 | 2017 | 101 | 0.030 |
Why?
|
| Retreatment | 1 | 2018 | 598 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2021 | 1867 | 0.030 |
Why?
|
| Goserelin | 1 | 2017 | 126 | 0.030 |
Why?
|
| Pregnant Women | 1 | 2021 | 576 | 0.030 |
Why?
|
| Th1 Cells | 1 | 2021 | 1040 | 0.030 |
Why?
|
| Comorbidity | 2 | 2021 | 10580 | 0.030 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2017 | 133 | 0.030 |
Why?
|
| Retrospective Studies | 5 | 2023 | 81635 | 0.030 |
Why?
|
| Social Class | 1 | 2005 | 2007 | 0.030 |
Why?
|
| Vasculitis | 1 | 2020 | 528 | 0.030 |
Why?
|
| Hypersensitivity | 1 | 2005 | 1169 | 0.030 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 538 | 0.030 |
Why?
|
| Histamine H2 Antagonists | 1 | 2017 | 168 | 0.030 |
Why?
|
| United States | 5 | 2022 | 72951 | 0.030 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2017 | 274 | 0.030 |
Why?
|
| Antigens, Viral | 1 | 1999 | 995 | 0.030 |
Why?
|
| Leuprolide | 1 | 2017 | 310 | 0.030 |
Why?
|
| Internationality | 1 | 2021 | 1006 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2020 | 1182 | 0.030 |
Why?
|
| Medical Errors | 1 | 2003 | 1260 | 0.030 |
Why?
|
| Aged | 7 | 2022 | 171343 | 0.030 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2018 | 497 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2023 | 2115 | 0.030 |
Why?
|
| International Cooperation | 1 | 2020 | 1434 | 0.030 |
Why?
|
| Tonsillectomy | 1 | 2017 | 281 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 2039 | 0.030 |
Why?
|
| Nephrocalcinosis | 1 | 2013 | 51 | 0.030 |
Why?
|
| Age of Onset | 1 | 2020 | 3342 | 0.030 |
Why?
|
| Aromatase Inhibitors | 1 | 2017 | 519 | 0.030 |
Why?
|
| Carcinoma | 1 | 2004 | 2324 | 0.030 |
Why?
|
| Premenopause | 1 | 2017 | 1039 | 0.030 |
Why?
|
| Specialization | 1 | 2017 | 779 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2018 | 2659 | 0.020 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2020 | 1750 | 0.020 |
Why?
|
| Lymphatic Diseases | 1 | 2013 | 318 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 6307 | 0.020 |
Why?
|
| Osteogenesis Imperfecta | 1 | 1992 | 81 | 0.020 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2017 | 1142 | 0.020 |
Why?
|
| Risk Factors | 3 | 2023 | 74881 | 0.020 |
Why?
|
| Thyroid Neoplasms | 1 | 2004 | 2355 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2020 | 1949 | 0.020 |
Why?
|
| Self Report | 1 | 2022 | 3771 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2020 | 3227 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2022 | 3853 | 0.020 |
Why?
|
| Up-Regulation | 1 | 1999 | 4142 | 0.020 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 2534 | 0.020 |
Why?
|
| Public Health | 1 | 2003 | 2681 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2017 | 2425 | 0.020 |
Why?
|
| Estradiol | 1 | 2017 | 1947 | 0.020 |
Why?
|
| Androgens | 1 | 2017 | 1280 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 2727 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2023 | 4784 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2016 | 1276 | 0.020 |
Why?
|
| Forecasting | 1 | 2018 | 2936 | 0.020 |
Why?
|
| Consensus | 1 | 2018 | 3208 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2020 | 3077 | 0.020 |
Why?
|
| Postmenopause | 1 | 2017 | 2517 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2021 | 3114 | 0.020 |
Why?
|
| Research Design | 1 | 2003 | 6207 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2021 | 4427 | 0.020 |
Why?
|
| Treatment Outcome | 3 | 2022 | 65273 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2020 | 12064 | 0.020 |
Why?
|
| Radiography, Thoracic | 1 | 2013 | 1320 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2017 | 2234 | 0.020 |
Why?
|
| Testosterone | 1 | 2017 | 2495 | 0.020 |
Why?
|
| Glycosaminoglycans | 1 | 1988 | 611 | 0.010 |
Why?
|
| Incidence | 1 | 2023 | 21525 | 0.010 |
Why?
|
| Boston | 1 | 2016 | 9346 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2021 | 22248 | 0.010 |
Why?
|
| Collagen | 1 | 1992 | 2635 | 0.010 |
Why?
|
| Sex Factors | 1 | 2017 | 10619 | 0.010 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2004 | 151 | 0.010 |
Why?
|
| Systems Integration | 1 | 2004 | 425 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 1988 | 2677 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 4056 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2016 | 6612 | 0.010 |
Why?
|
| Bone and Bones | 1 | 1992 | 2559 | 0.010 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 1988 | 1494 | 0.010 |
Why?
|
| Subtraction Technique | 1 | 2004 | 513 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2021 | 26389 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2004 | 20708 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 1999 | 22352 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 15416 | 0.010 |
Why?
|
| Calcium | 1 | 2013 | 5783 | 0.010 |
Why?
|
| Animals | 3 | 2023 | 168930 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 7431 | 0.010 |
Why?
|
| Pregnancy | 1 | 2021 | 30237 | 0.010 |
Why?
|
| Phenotype | 1 | 2016 | 16724 | 0.010 |
Why?
|
| Time Factors | 2 | 2018 | 40149 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2022 | 54871 | 0.010 |
Why?
|
| Prognosis | 1 | 2018 | 29948 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2018 | 24295 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2022 | 59550 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2004 | 2901 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2004 | 2704 | 0.010 |
Why?
|
| Cyanogen Bromide | 1 | 1992 | 75 | 0.010 |
Why?
|
| Mice | 1 | 1999 | 81889 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1992 | 1729 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 14652 | 0.000 |
Why?
|
| Dermatan Sulfate | 1 | 1988 | 43 | 0.000 |
Why?
|
| Prevalence | 1 | 2005 | 15835 | 0.000 |
Why?
|
| Chondroitin Sulfates | 1 | 1988 | 174 | 0.000 |
Why?
|
| Heparitin Sulfate | 1 | 1988 | 223 | 0.000 |
Why?
|
| Rats, Inbred Strains | 1 | 1988 | 2078 | 0.000 |
Why?
|
| Reproducibility of Results | 1 | 2004 | 20144 | 0.000 |
Why?
|
| Ascorbic Acid | 1 | 1988 | 658 | 0.000 |
Why?
|
| Follow-Up Studies | 1 | 2004 | 39309 | 0.000 |
Why?
|
| Aorta | 1 | 1988 | 2043 | 0.000 |
Why?
|
| Skin | 1 | 1992 | 4499 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1988 | 18984 | 0.000 |
Why?
|
| Rats | 1 | 1988 | 23717 | 0.000 |
Why?
|